Roche’s Hemlibra shows sustained bleed control in children
Roche’s Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Read More
Tag: inhibitors
Trial findings back wider use of Roche’s Hemlibra
Data from two late-stage studies further support use of Roche’s Hemlibra in a much broader population of haemophilia patients.
Read More
Roche’s haemophilia drug cut bleeds by 87 percent in trial
Roche has presented a new batch of data showing that its experimental bispecific monoclonal antibody emicizumab significantly reduced bleeds in patients with haemophilia A and inhibitors to factor VIII.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
